Isis buys drug funding entity
From Times Wire Services
Isis Pharmaceuticals Inc. has acquired all outstanding shares of Symphony GenIsis for $120 million in cash and stock.
Isis also reacquired full ownership of its cholesterol-lowering drug Isis 301012, the Carlsbad, Calif., company said.
Symphony GenIsis was formed in April 2006 by Symphony Capital Partners to fund development of three Isis drugs.
